Neurological - oncology - SA Health Approved Cancer Chemotherapy Protocol Register
Glioma
Protocol | Administration at chemotherapy unit level | Review Date |
---|---|---|
Anaplastic glioma PCV (procarbazine lomustine vinCRISTine) | Medium | August 2025 |
Anaplastic glioma temozolomide following radiation | Low | August 2023 |
Glioblastoma recurrent bevacizumab | Low | August 2023 |
Glioblastoma recurrent lomustine | Low | August 2023 |
Glioblastoma temozolomide chemoradiation (part 1) | Low | February 2023 |
Glioblastoma temozolomide following chemoradiation (part 2) | Low | February 2023 |
Glioblastoma temozolomide following short course chemoradiation (elderly patients) (part 2) | Low | February 2023 |
Glioblastoma temozolomide short course chemoradiation (elderly patients) (part 1) | Low | August 2023 |
Glioma high grade or recurrent temozolomide | Low | February 2023 |
Glioma high grade recurrent PCV (procarbazine lomustine vinCRISTine) | Medium | August 2023 |
Glioma low grade PCV (procarbazine lomustine vinCRISTine) | Medium | August 2023 |
Notes
- Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
- Fluorouracil pumps may be connected/disconnected at low-risk units
- Non-formulary drug included in the protocol
- Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.